### THEMATIC



**Pierre BLANCHET,** *Head of Investment Intelligence* 




Aurelien STRENTA, Emerging Markets Analyst (V.I.E)

# **Geopolitics of the vaccine**

Eighteen months after the first Covid-19 cases hit China, the outbreak is still uncontrolled globally and remains the main source of economic uncertainty outside Northern Asia. As long as there is no treatment, access to effective vaccines is the main factor in returning to a 'normal' life. Only a handful of countries can produce jabs on a large scale, whereas we already know it will take years to reach herd immunity. Therefore, vaccines have become a form of geopolitical soft power, which exacerbates or redesigns the influence of the US, Europe, China and Russia.

More than a year after the outbreak shut down the world, new lockdown measures are perceived as political failures. They have a negative impact on the economy but also on social cohesion and probably people's mental health. Yet, as long as there is no treatment for Covid-19 and mass vaccination does not bring herd immunity, mobility restrictions and social distancing are the only solutions available. Hence, the race by governments to get access to effective vaccines in high volumes. As we speak, there are seven vaccines approved for full usage, six authorised for limited use, 23 in phase 3 development with large-scale efficacy tests, and more than 80 in phase 1 or 2. Therefore, it is likely that the number of available vaccines will double in the second quarter.




So far, 160 million people have been fully vaccinated according to OWD (University of Oxford), i.e., 2% of the world population, out of which 60% are living in the US or the European Union, which account for less than 10% of the world population (see Graph 1). A few countries are running ahead in the vaccine race, such as Israel, where 61% of the population has received at least one dose, the UK (46%) or the US (36%), but Europe is far behind, with 12% to 13% of the population who has received a jab. Emerging countries are even further behind, with less than 5% in India, Russia or Indonesia. China doesn't officially have Covid cases... and we don't

have accurate vaccination numbers yet, but it's unlikely that more than 5% of the 1.4 billion Chinese have got a first jab at the time of this writing. COVAX<sup>1</sup> is running behind schedule, therefore the vast majority of the world population won't be vaccinated by the end of the year. Moreover, variants, the low duration of immunity, and the likely resurgence of the outbreak over the coming years means that we might need to be vaccinated regularly to keep our immune system effective.

There are two consequences to this: (1) it will take years to reached global herd immunity, (2) vaccines are very powerful geopolitical weapons.

<sup>1</sup> COVAX is the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator. The ACT Accelerator is a ground-breaking global collaboration to accelerate the development, production, and equitable access to COVID-19 tests, treatments, and vaccines. COVAX is co-led by Gavi, the Coalition for Epidemic Preparedness Innovations (CEPI) and WHO. Its aim is to accelerate the development and manufacture of COVID-19 vaccines, and to guarantee fair and equitable access for every country in the world.

### 1/ Uneven vaccination among regions



Source: Our World in Data, World Bank, Amundi Research Data as of April 9 2021


## THIS MONTH'S TOPIC

While through 2020, China came out more victorious from its successful management of the domestic health crisis and strengthened its influence as the leading economy in the global recovery, 2021 has been more favourable for the US and Europe.

The unprecedented technological innovation of mNRA vaccine development is leading to more domestic control of the virus and a strong comparative advantage in the geopolitics of vaccine diplomacy. Among the countries that have reserved enough vaccines to cover more than half of their population older than 15 years, 100% of vaccines reserved in Advanced Economies (AEs) are from these countries. For instance, in the US the breakdown is roughly 50% Pfizer/BioNTech and 50% Moderna. But in emerging economies, 32% of vaccines ordered are from China and 7% from Russia (see Graphs 2 and 3). For instance, in CEEMA 50% of vaccines reserved have come from China so far<sup>2</sup>.

<sup>2</sup> According to Duke Global Health Innovation Center as of April 9 2021

### 2/ Vaccine providers' country by region



Source: Duke Global Health Innovation Center, Amundi as of April 9 2021

### 3/ EM Distribution of vaccines reserved per country's providers as of total (%)

South Africa Kuwait Costa Rica Panama Dominican Republic Taiwan South Korea Israel Thailand Ecuador Colombia Philippines Brazil Mexico Sri Lanka Morocco Uruguay Malaysia Hong Kong Peru Argentina Indonesia Vietnam Chile Egypt Turkey Azerbaijan 0 10 20 30 40 50 60 70 80 90 100 US+Europe China Russia India

In EM, 32% of vaccines ordered are from China and 7% from Russia

Source: Amundi Research, Duke Global Health Innovation Center as of April 9 2021

# THIS MONTH'S TOPIC

Vaccines are very powerful geopolitical weapons

The first strategic game for Europe and the US is to protect their own populations, close their markets by approving only AE products (see Russian SputnikV ban), and very quickly bring vaccines to Africa, Latin America and the Middle East to contain Chinese and Russian influence there. However, while AEs are still focusing on managing their domestic crises, China and Russia are taking advantage to fill the gap of short supply and long waiting periods in the emerging world, and, by this, consolidate diplomatic ties. The bilateral agreements between Russia and the EU's eastern countries (Hungary, Slovakia, and possibly the Czech Republic<sup>3</sup>) to access Sputnik V is a good example. Most importantly, it sheds light on the soft-power that vaccines can procure. Indeed, Russia may gain inside support to lessen the likelihood of EU's sanctions.<sup>4</sup> Nevertheless, Chinese vaccines recorded disappointing results abroad (Brazil and Chile), and both countries still need to vaccinate their own population (China has set a target of 40% by the end of June), or risk further outbreaks. The US, whose vaccination campaign is successfully running ahead of schedule, is organising with the other "quad's members"

(Australia, India, and Japan) a common initiative to export vaccines in the Indo-Pacific that may counterbalance China's influence.<sup>5</sup>

The second strategic game is around contracts, i.e., price, volume and copyrights and is happening within advanced economies. In Europe, AstraZeneca (AZN) produces half of jabs. Since the AZN vaccine has a lower efficacy rate and has lost some public support, European demand for US patented vaccines is very high. As an early and successful "investor", the US wants to protect its return. The EU, which has been focusing on price and equal distribution but with the "wrong weapon", is under huge internal pressure to accelerate vaccination rollouts and produce US vaccines in its own labs. Moreover, US pharma companies that are distributing available vaccines are now working on boosters, next-gen vaccines and paediatric trials, which will be key to reaching full immunity. The US have the best products and have vaccinated a larger share of their population, so they are on the road to victory in this Covid-19 vaccine geopolitical game.

Finalised on 15 April 2021

<sup>3</sup> Czech PM names fourth health minister amid Sputnik vaccine strife, Reuters – Apr. 7, 2021

- <sup>4</sup> Vaccine diplomacy will bring modest gains, Eurasia Group Apr. 1, 2021
- <sup>5</sup> Vaccine initiative seeks to boost the quad's influence in the Indo-Pacific, Eurasia Group Mar. 5, 2021

Vaccines' efficacy									
Company	Pfizer- BioNTech	Moderna	AstraZeneca	1%1	Novavax	Sinopharm	Sinovac	CanSino Biologics	Gamaleya
Country	US & Germany	US	UK & Sweden	US & Belgium	US	China	China	China	Russia
Efficacy rate	91%	>90%	76% (U.S study)	US: 72%, BRL: 68%, SAF: 64%	96%	79% no details published of Phase 3 trial.	BRL: 51%, TKY: 91%, CHL: <70% no publication of trials' details	65% no details published of Phase 3 trial and efficacy could decrease over time according to the chief scientific officer	92%
Variant efficacy									
Brazilian variant	expected to be effective	expected to be effective	effective				may not be effective		
South-Africa variant	slighlty less effective	slighlty less effective	not effective (however, small trial)	less effective	49%	slightly less effective but no publication in a medical journal			

Source: NY Times, Reuters, Amundi Research





May 2021 #05

# **Amundi Research Center**



#### DISCLAIMER

The MSCI information may only be used for your internal use, may not be reproduced or redisseminated in any form and may not be used as a basis for or a component of any financial instruments or products or indices. None of the MSCI information is intended to constitute investment advice or a recommendation to make (or refrain from making) any kind of investment decision and may not be relied on as such. Historical data and analysis should not be taken as an indication or guarantee of any future performance analysis, forecast or prediction. The MSCI information is information as such. Historical data and analysis should not be taken as an indication or guarantee of any future performance analysis, forecast or prediction. The MSCI information is provided on an "as is" basis and the user of this information assumes the entire risk of any use made of this information. MSCI, each of its affiliates and each other person involved in or related to compiling, computing or creating any MSCI information (collectively, the "MSCI Parties") expressly disclaims all warranties (including, without limitation, any warranties of originality, accuracy, completeness, timeliness, non-infringement, merchantability and fitness for a particular purpose) with respect to this information. Without limiting any of the foregoing, in no event shall any MSCI Party have any liability for any direct, indirect, special, incidental, punitive, consequential (including, without limitation, lost profits) or any other damages. (www.mscibarra.com).

In the European Union, this document is only for the attention of "Professional" investors as defined in Directive 2004/39/EC dated 21 April 2004 on markets in financial instruments ("MIFID"), to investment services providers and any other professional of the financial industry, and as the case may be in each local regulations and, as far as the offering in Switzerland is concerned, a "Qualified Investor" within the meaning of the provisions of the Swiss Collective Investment Schemes Act of 23 June 2006 (CISA), the Swiss Collective Investment Schemes Ordinance of 22 November 2006 (CISO) and the FINMA's Circular 08/8 on Public Advertising under the Collective Investment Schemes legislation of 20 November 2008. In no event may this material be distributed in the European Union to non "Professional" investors as defined in the MIFID or in each local regulation, or in Switzerland to investors who do not comply with the definition of "qualified investors" as defined in the applicable legislation and regulation. This document is not intended for citizens or residents of the United States of America or to any "U.S. Person", as this term is defined in SEC Regulation S under the U.S. Securities Act of 1933. This document neither constitutes an offer to buy nor a solicitation to sell a product, and shall not be considered as an unlawful solicitation or an investment advice. Amundi accepts no liability whatsoever, whether direct or indirect, that may arise from the use of information contained in this material. Amundi can in no way be held responsible for any decision or investment made on the basis of information contained in this material. Amundi can in no way be held responsible for any decision or entity in any country or jurisdiction which would subject Amundi or any of "the Funds", to any registration requirements within these jurisdictions or where it might be considered as unlawful. Accordingly, this material is for distribution solely in jurisdictions where permitted and to persons who may receive it without brea

You have the right to receive information about the personal information we hold on you. You can obtain a copy of the information we hold on you by sending an email to info@amundi.com. If you are concerned that any of the information we hold on you is incorrect, please contact us at info@amundi.com.

Document issued by Amundi Asset Management, "société par actions simplifiée"- SAS with a capital of €1,086,262,605 - Portfolio manager regulated by the AMF under number GP04000036 - Head office: 90 boulevard Pasteur - 75015 Paris - France - 437 574 452 RCS Paris - www.amundi.com Photo credit: ©MDelporte - iStock/Getty Images Plus - marcutti

#### Chief editor

BLANQUÉ Pascal, Group Chief Investment Officer

Editor

DEFEND Monica, Global Head of Research

#### With Global Research contributers

AINOUZ Valentine, Deputy Head of Developed Markets Strategy Research, CFA BELLAICHE Mickael, Fixed Income and Credit Research Strategist BERARDI Alessia, Head of Emerging Macro and Strategy Research BERTONCINI Sergio, Senior Fixed Income Research Strategist BLANCHET Pierre, Head of Investment Intelligence BOROWSKI Didier, Head of Global Views CESARINI Federico, Cross Asset Research Strategist DELBO' Debora, EM Macro Strategist DI SILVIO Silvia, Macro Strategist DROZDZIK Patryk, EM Macro Strategist

With the Amundi Insights Unit contribution BERTINO Claudia, Head of Amundi Investment Insights Unit CARULLA POL, Amundi Investment Insights Unit

Conception & production BERGER Pia, Research PONCET Benoit, Research

#### Deputy-Editors

BLANCHET Pierre, Head of Investment Intelligence BOROWSKI Didier, Head of Global Views

GEORGES Delphine, Senior Fixed Income Research Strategist HERVÉ Karine, EM Macro Strategist HUANG Claire, EM Macro Strategist LEONARDI Michele, Cross Asset Research Junior Analyst MIJOT Éric, Head of Developed Markets Strategy Research PERRIER Tristan, Global Views PORTELLI Lorenzo, Head of Cross Asset Research STRENTA Aurelien, Emerging Market Analyst (V.I.E) USARDI Annalisa, Senior Economist Cross Asset Research VARTANESYAN Sosi, Sovereign Analyst, Emerging Macro & Strategy Research

FIOROT Laura, Deputy Head of Amundi Investment Insights Unit DHINGRA Ujjwal, Amundi Investment Insights Unit PANELLI Francesca, Amundi Investment Insights Unit

Document for the exclusive attention of professional clients, investment services providers and any other professional of the financial industry